QuidelOrtho on Friday announced preliminary revenues for the fourth quarter of 2022, saying it expects to book between $853 million and $868 million.
The company anticipates Q4 COVID-19 product revenue between $124 million and $134 million, and non-COVID-19 product revenue between $729 million and $734 million.
For full-year 2022, QuidelOrtho said it expects revenues between $4,038 million and $4,053 million. Of the total, it anticipates COVID-19 product revenues between $1,441 million and $1,451 million, and non-COVID-19 product revenues between $2,597 million and $2,602 million.
“Notably, our strong positioning in the point-of-care market with both the Sofia platform and QuickVue Flu Test enabled us to serve patients in a strong respiratory season, which drove substantial revenue growth,” Douglas Bryant, the firm’s president and CEO, said in a statement.
The San Diego-based firm said it will report final fourth quarter and full-year 2022 financial results on February 15.